Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
about
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaRitonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerRole of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain.Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.Effects of 5-Amyno-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1,2-dihydro-3H-pyrrol-3-one Intake on Digestive System in a Rat Model of Colon Cancer.
P2860
Q33411001-B34157A1-262D-45A0-A8BB-BC2044EBC86CQ36949546-D2CC46FE-7451-4E4B-9410-889BDF7C8AECQ37193103-142213E5-226D-4321-A61F-4CEA340280FCQ37217268-7E3E711E-542E-4969-8DE8-F424C3096425Q38684505-DED2DD2A-24EC-4442-9AF7-E70684AEFFC2Q40003126-A0D6221E-0EE7-4786-B39E-862BB4EC4ADAQ43515674-22C3A35B-4D49-4AEA-9CA4-16FD94E803DCQ47937814-563CC26D-4F04-4D70-8F7E-10CF69ECCD14Q55070162-28BC5DC6-5E4B-4CFE-B2CD-17C1EB6D9CA2Q55173344-05344C1E-A5A2-49B6-97FA-2D8D07B434E5
P2860
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
@en
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib.
@nl
type
label
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
@en
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib.
@nl
prefLabel
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
@en
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib.
@nl
P2093
P2860
P356
P1476
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
@en
P2093
Chang-xiao Liu
Guang-bo Ge
Li-ming Wang
Liang-liang Zhu
Pei-pei Dong
Yan-qing Qu
Zhong-ze Fang
P2860
P2888
P304
P356
10.1038/APS.2010.218
P577
2011-03-01T00:00:00Z